Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million

Reuters

昨天

Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million

HeartCare published an annual results announcement for the year ended Dec. 31, 2025.
Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.
Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.
Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.
Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2622593988"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622593988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622593988?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622593988","market":"nz","top_or_hot":-1,"title":"Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          HeartCare published an annual results announcement for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.\n        </li>\n<li>\n          Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.\n        </li>\n<li>\n          Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.\n        </li>\n<li>\n          Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-26 18:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          HeartCare published an annual results announcement for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.\n        </li>\n<li>\n          Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.\n        </li>\n<li>\n          Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.\n        </li>\n<li>\n          Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9K5rFt:1","article_id":"2622593988","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622593988","pubTimestamp":1774521700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HeartCare published an annual results announcement for the year ended Dec. 31, 2025.Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","06609":"心玮医疗-B","BK1587":"次新股","BK1100":"医疗保健设备"},"translate_title":"上海心康医疗科技2025财年税前利润跃升至人民币8600万元；收入增长46.9%至人民币4.08亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06609":0.9},"content_text":"Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million\n    \n\n\n          HeartCare published an annual results announcement for the year ended Dec. 31, 2025.\n        \n\n          Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.\n        \n\n          Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.\n        \n\n          Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.\n        \n\n          Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}